JP2024517769A5 - - Google Patents

Info

Publication number
JP2024517769A5
JP2024517769A5 JP2023566850A JP2023566850A JP2024517769A5 JP 2024517769 A5 JP2024517769 A5 JP 2024517769A5 JP 2023566850 A JP2023566850 A JP 2023566850A JP 2023566850 A JP2023566850 A JP 2023566850A JP 2024517769 A5 JP2024517769 A5 JP 2024517769A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
ring
alkoxy
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566850A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517769A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026832 external-priority patent/WO2022232459A1/en
Publication of JP2024517769A publication Critical patent/JP2024517769A/ja
Publication of JP2024517769A5 publication Critical patent/JP2024517769A5/ja
Pending legal-status Critical Current

Links

JP2023566850A 2021-04-30 2022-04-28 Lpaアンタゴニストとしての新規トリアゾール-ピリジン置換ピロリジニル及びテトラヒドロ-2h-ピラニル酢酸化合物 Pending JP2024517769A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021091510 2021-04-30
CNPCT/CN2021/091510 2021-04-30
PCT/US2022/026832 WO2022232459A1 (en) 2021-04-30 2022-04-28 Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists

Publications (2)

Publication Number Publication Date
JP2024517769A JP2024517769A (ja) 2024-04-23
JP2024517769A5 true JP2024517769A5 (cg-RX-API-DMAC7.html) 2025-05-01

Family

ID=81748636

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566850A Pending JP2024517769A (ja) 2021-04-30 2022-04-28 Lpaアンタゴニストとしての新規トリアゾール-ピリジン置換ピロリジニル及びテトラヒドロ-2h-ピラニル酢酸化合物

Country Status (10)

Country Link
US (1) US20250230140A1 (cg-RX-API-DMAC7.html)
EP (1) EP4330249A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024517769A (cg-RX-API-DMAC7.html)
KR (1) KR20240044386A (cg-RX-API-DMAC7.html)
CN (1) CN117751106A (cg-RX-API-DMAC7.html)
AU (1) AU2022264579A1 (cg-RX-API-DMAC7.html)
CA (1) CA3218258A1 (cg-RX-API-DMAC7.html)
IL (1) IL308035A (cg-RX-API-DMAC7.html)
MX (1) MX2023012830A (cg-RX-API-DMAC7.html)
WO (1) WO2022232459A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023109878A1 (zh) * 2021-12-15 2023-06-22 武汉人福创新药物研发中心有限公司 三氮唑类lpar1拮抗剂及其用途
CN121773091A (zh) * 2023-09-08 2026-03-31 西藏海思科制药有限公司 杂芳环衍生物的lpar1拮抗剂及其用途
IL326963A (en) * 2023-09-08 2026-05-01 Haisco Pharmaceutical Group Co Ltd LPAR1 antagonist and its use
WO2026119206A1 (zh) * 2024-12-05 2026-06-11 海思科医药集团股份有限公司 Lpar1拮抗剂药物组合物及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7369125B2 (ja) * 2017-12-19 2023-10-25 ブリストル-マイヤーズ スクイブ カンパニー Lpaアンタゴニストとしてのイソキサゾールo-架橋カルバモイルシクロヘキシル酸
CA3085561A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
CN111434655A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 溶血磷脂酸受体拮抗剂及其制备方法
KR20220024548A (ko) * 2019-06-18 2022-03-03 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 트리아졸 카르복실산
IL300525A (en) * 2020-08-11 2023-04-01 Viva Star Biosciences Ltd Triazole-pyridinyl-substituted azacyclohexyl acetic acid compounds as LPA receptor antagonists

Similar Documents

Publication Publication Date Title
JP2023544476A5 (cg-RX-API-DMAC7.html)
JP2020510015A5 (cg-RX-API-DMAC7.html)
JP2014531434A5 (cg-RX-API-DMAC7.html)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
US20080182845A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2019094345A5 (cg-RX-API-DMAC7.html)
JP2018524339A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
JP2021508686A5 (cg-RX-API-DMAC7.html)
JP2013532652A5 (cg-RX-API-DMAC7.html)
JP2013502431A5 (cg-RX-API-DMAC7.html)
JP2020517711A5 (cg-RX-API-DMAC7.html)
JP2017516826A5 (cg-RX-API-DMAC7.html)
JP2020510010A5 (cg-RX-API-DMAC7.html)
JP2018536648A5 (cg-RX-API-DMAC7.html)
JP2018529745A5 (cg-RX-API-DMAC7.html)
JP2021535174A5 (cg-RX-API-DMAC7.html)
JP2022500470A5 (cg-RX-API-DMAC7.html)
JP2021535177A5 (cg-RX-API-DMAC7.html)
JP2009523841A5 (cg-RX-API-DMAC7.html)
JP2013508452A5 (cg-RX-API-DMAC7.html)
US20160175316A1 (en) Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
JP2024507414A5 (cg-RX-API-DMAC7.html)
JP2023504544A5 (cg-RX-API-DMAC7.html)
JP2015508068A5 (cg-RX-API-DMAC7.html)